"近期，公司将重点加快核心产品TSN1611的临床开发及商业化进程。同时，将通过包括对外授权、区 域权益合作及联合开发协议在内的灵活合作安排，积极推进外部合作，以实现公司技术平台及产品管线 资产的全球价值最大化。"泰励生物称。 1月29日，泰励生物有限公司向港交所递交上市申请材料。 上市申请材料显示，泰励生物是一家成立于2017年的处于临床阶段的生物制药公司，专注于发现与开发 创新肿瘤疗法。公司核心候选药物TSN1611是一款高选择性的口服KRAS G12D抑制剂。2024年、2025 年前三季度，公司净亏损分别为7046.1万元、1.23亿元。 聚焦小分子药物及ADC候选药物 根据上市申请材料，泰励生物的核心业务模式是围绕肿瘤治疗领域开展创新药物的自主发现与开发，重 点聚焦小分子药物及ADC（抗体药物偶联物）候选药物。 截至2026年1月23日，公司药物组合包含四种候选药物，包括一款处于2期临床试验阶段的核心产品 TSN1611，一款额外临床阶段候选药物TSN222和两款临床前期候选药物TSNA1789、TSNA3339。 其中，公司核心候选药物TSN1611目前正在美国及中国开展2期临床试验，并计划在中国 ...

据港交所1月29日披露，泰励生物有限公司(简称：泰励生物)向港交所主板递交上市申请，中信证券为其独家保荐人。 公司简介 招股书披露，泰励生物是一家成立于2017年的处于临床阶段的生物制药公司，专注于发现与开发创新肿瘤疗法。公司的药物组合包含四种候选药物，包括一 款处于2期临床试验阶段的核心产品TSN1611，一款额外临床阶段候选药物TSN222和两款临床前期候选药物TSNA1789和TSNA3339。公司的核心候选药物 TSN1611是一款高选择性的口服KRAS G12D抑制剂。KRAS G12D作为最常见的致癌驱动突变之一，在历史上始终是治疗难点。TSN1611目前正在美国及中 国开展2期临床试验，并计划在中国推进用于治疗非小细胞肺癌（「NSCLC」）的关键性注册临床试验。 公司正在开发核心产品TSN1611和其他候选药物。该领域具有来自国内和国际制药公司的激烈竞争，这些制药公司可能拥有处于类似或更先进的临床阶段的 候选药物。公司面临激烈的竞争及快速的技术变革，且竞争对手可能开发比公司更先进或更有效的类似疗法，这可能会对公司的财务状况及成功将公司的候 选药物商业化的能力造成不利影响。 值得注意是，公司可能无 ...

据港交所1月29日披露，泰励生物有限公司(简称：泰励生物)向港交所主板递交上市申请，中信证券为其独家保荐人。招股书披露，泰励 生物是一家成立于2017年的处于临床阶段的生物制药公司，专注于发现与开发创新肿瘤疗法。公司的药物组合包含四种候选药物，包括 一款处于2期临床试验阶段的核心产品TSN1611，一款额外临床阶段候选药物TSN222和两款临床前期候选药物TSNA1789和TSNA3399, 公司的核心候选药物TSN1611是一款高选择性的口服KRAS G12D抑制剂。KRAS G12D作为最常见的致感驱动突变之一，在历史上始终是 治疗难点。TSN1611目前正在美国及中国开展2期临床试验，并计划在中国推进用于治疗非小细胞肺癌("NSCLC")的关键性注册临床试 验。 Tyligand Bioscience Ltd. 泰 勵 生 物 有 限 公 司 * (於開曼群島註冊成立的有限公司) [編纂] 獨家保薦人 ·[編纂] 4 中信证券 「編纂]的「編纂]股份數目 : 「編纂]股股份(視乎[編纂]行使與否而定) 「編纂]數目 「編纂」股股份(可予重新分配) ·· 國際[編纂]數目 . 「編纂]股股份(可予重新分配 ...

泰 勵 生 物 有 限 公 司 * 智通财经APP获悉，据港交所1月29日披露，泰励生物有限公司(简称：泰励生物)向港交所主板递交上市申请，中信证券为其独家保荐 人。招股书披露，泰励生物是一家成立于2017年的处于临床阶段的生物制药公司，专注于发现与开发创新肿瘤疗法。公司的药物组合包 含四种候选药物，包括一款处于2期临床试验阶段的核心产品7SN1611，一款额外临床阶段候选药物TSN222和两款临床前期候选药物 TSNA1789和TSNA3339。公司的核心候选药物TSN1611是一款高选择性的口服KRAS G12D抑制剂。KRAS G12D作为最常见的致感驱动突 变之一，在历史上始终是治疗难点。TSN1611目前正在美国及中国开展2期临床试验，并计划在中国推进用于治疗非小细胞肺癌 （「NSCLC」）的关键性注册临床试验。 Tyligand Bioscience Ltd. 4 中信证券 (於開曼群島註冊成立的有限公司) 「編纂]的「編纂]股份數目 : 「編纂]股股份(視乎[編纂]行使與否而定) 「編纂]數目 「編纂」股股份(可予重新分配) ·· 國際[編纂]數目 . 「編纂]股股份(可予重新分配及視乎[編 纂 ...

Core Viewpoint - The stock price of 加科思-B (01167) increased by 6.17% to HKD 8.09, with a trading volume of HKD 17.6587 million, following the announcement of a capital increase and equity transfer agreement [1][5] Group 1: Financial Developments - 加科思's subsidiary, 北京加科思, received a first payment of RMB 125 million from 海松资本 as part of the capital increase and equity transfer agreement, enhancing the group's cash reserves [1][5] - The influx of funds is expected to support the development of innovative cancer therapy pipelines [1][5] Group 2: Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, were published in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1][5] - This publication marks the first systematic clinical data on the combination of KRAS G12C and SHP2 dual oral small molecule therapy to be featured in such a high-profile journal [1][5]

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, with a current price of HKD 8.04 and a trading volume of HKD 8.1525 million. The company has received a substantial payment that enhances its cash reserves and supports its ongoing research in innovative cancer therapies [1]. Group 1 - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, which bolsters the group's cash reserves [1]. - The receipt of this payment is expected to facilitate the advancement of the company's pipeline for innovative cancer therapies [1]. Group 2 - Gossamer Bio announced the publication of clinical I/IIa study results for its self-developed KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312 (Sitneprotafib) in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1]. - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has been featured in such a reputable journal [1].

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, attributed to positive developments in the company's financial and clinical research activities [1] Financial Developments - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the company's innovative oncology therapy pipeline [1] Clinical Research Achievements - Gossamer Bio announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, Glecirasib, in combination with the SHP2 inhibitor, JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]

Core Viewpoint - Apollomics Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly for patients with limited treatment options, and is currently advancing its lead candidate APL-101 (vebreltinib) through global clinical trials [1][3]. Group 1: Company Overview - Apollomics has 9 drug candidates in its pipeline, with 6 in clinical development targeting challenging cancers such as lung cancer and brain cancer [1]. - The company employs a strategy that combines targeted therapies, immuno-oncology, and innovative mechanisms of action to overcome resistance and achieve clinically meaningful efficacy [1]. Group 2: Recent Developments - On August 28, 2025, Apollomics announced plans to terminate all clinical trial activities related to APL-101 due to financial issues and sought shareholder approval for liquidation [2]. - Following a PIPE investment of $4.1 million on September 3, 2025, the company appointed a new board and management team, including Howard Chen as CEO and Alex Chen as COO [2]. Group 3: Clinical Trials and Future Plans - After securing additional funding and a new management team, Apollomics canceled its liquidation plans and will continue its existing operations, including the global development of APL-101 [3]. - The company is committed to completing the SPARTA clinical trials for APL-101, which are crucial for maximizing its therapeutic potential across various tumor types and supporting regulatory submissions in major markets [4]. - Apollomics plans to leverage its partnerships in China to advance regulatory submissions for APL-101 in emerging markets outside of Southeast Asia and the Middle East [4]. Group 4: Workforce and Operations - Apollomics currently has 12 full-time employees, with plans to increase the workforce to 15 by October 31, 2025, while also reducing staff in mainland China and reallocating resources to the U.S. and Taiwan [4].